Tempus broadens collaboration with BMS for clinical trials

Tempus AI has expanded its strategic partnership with BMS to optimise clinical trial designs across oncology and neuroscience programmes. The initiative is initially supporting solid tumour oncology projects, focusing on indications such as colon and lung. The collaboration seeks to use AI, multimodal real-world data, and data science methodologies to optimise trial design. Credit: metamorworks / Shutterstock.com. Tempus AI has expanded its strategic partnership with Bristol Myers Squibb (BMS) to optimise clinical trial designs across oncology and neuroscience programmes. The collaboration seeks to use AI, multimodal real-world data, and data science methodologies to optimise trial design and improve the Probability…

Source: Clinical Trials Arena